Pharmaceutical

AmyriAD leaves no leaf unturned with upcoming Phase III Alzheimer’s trials

The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.

Jan 5, 2024 - 18:00
AmyriAD leaves no leaf unturned with upcoming Phase III Alzheimer’s trials
The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.
Read the original article

Tags:

Previous Article

STAT+: Goldman Sachs launches $650 million fund for life sciences investments

Next Article

Signal: UK online pharmacies selling prescription drugs without proper checks

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA advisory panel votes in favor of Abbott’s new heart device

STAT+: FDA advisory panel votes in favor of Abbott’s ne...

Feb 13, 2024

Liver Transplant Rejection drugs in development, 2023

Nov 30, 2023

Junshi Biosciences, Dr. Reddy’s partner to develop and market toripalimab

Junshi Biosciences, Dr. Reddy’s partner to develop and ...

May 8, 2023